The haemoglobin glycation index (HGI) quantifies the interindividual variation in the propensity for glycation and is a predictor of diabetes complications and adverse effects of intensive glucose lowering. We investigated the relevance of HGI as independent predictor of complications by using data of the AleCardio trial. The AleCardio trial randomized 7226 type 2 diabetes patients with an acute coronary syndrome to aleglitazar or placebo. From 6458 patients with baseline glycated haemoglobin (HbA 1c ) and fasting plasma glucose (FPG), a linear regression equation, HbA 1c (%) ¼ 5.45 þ 0.0158 * FPG (mg/dl), was used to calculate predicted HbA 1c and derive HGI (¼ observed -predicted HbA 1c ). With multivariate Cox regression we examined the association with major adverse cardiac events, cardiovascular mortality, total mortality and hypoglycaemia, irrespective of treatment allocation, using HGI subgroups (low, intermediate and high) and HGI as continuous variable. Patients with high HGI were younger, more often nonCaucasian, had a longer duration of diabetes, showed more retinopathy and used insulin more often. Hypoglycaemia occurred less often in the low HGI subgroup, but this difference disappeared after adjustment for duration of diabetes, insulin and sulphonylurea use. Low HGI patients were at lower risk for cardiovascular mortality (hazard ratio 0.64; 95% confidence interval 0.44-0.93, p ¼ 0.020) and total mortality (hazard ratio 0.69; 95% confidence interval 0.50-0.95, p ¼ 0.025), as compared with high HGI patients. Every percentage increase in HGI was associated with a 16% increase in the risk for cardiovascular mortality (p ¼ 0.005). The association between HGI and mortality disappeared with additional adjustment for HbA 1c . HGI predicts mortality in diabetes patients with acute coronary syndromes, but no better than HbA 1c .
Introduction
Glycated haemoglobin (HbA 1c ) is the most commonly used marker of glycaemic control and a validated treatment target.
1, 2 The use of HbA 1c to guide treatment is mainly based on its relationship with microvascular complications, shown in both epidemiological and intervention studies. [3] [4] [5] [6] [7] [8] The effect of HbA 1c lowering on macrovascular complications is less consistent, with some studies showing a reduction in macrovascular events only with long term follow-up. [9] [10] [11] [12] Moreover, the safety and benefits of intensive HbA 1c lowering in type 2 diabetes came under debate, due to the results of a large HbA 1c lowering intervention study. In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, 13 intensive HbA 1c lowering was associated with a 22% relative increase in mortality, thereby limiting the use of HbA 1c as a one-size-fits-all treatment target and risk predictor.
14 Numerous post hoc analyses examined the unexpected ACCORD results, but no clear explanation emerged. [15] [16] [17] [18] [19] [20] Recently, Hempe and colleagues showed that the increased mortality due to intensive treatment was restricted to the ACCORD patients characterized by a high haemoglobin glycation index (HGI), which is the difference between observed HbA 1c and HbA 1c predicted from the regression equation between plasma glucose and HbA 1c in a particular population. 21 Furthermore, intensive treatment was not able to improve the primary composite outcome of major adverse cardiac events (MACEs) in these high HGI patients, whereas MACEs were diminished with intensive therapy among patients with intermediate or low HGI.
HGI is designed to quantify the interindividual variation in the propensity for haemoglobin glycation, known to exist in type 1 and 2 diabetes as well as in healthy individuals, since we lack an accurate laboratory glycation rate measurement. It is the difference between the observed HbA 1c and HbA 1c predicted by inserting time-matched fasting plasma glucose (FPG) in a population regression equation, based on the linear relation between HbA 1c and FPG. Thereby, HGI ¼ observed HbA 1c -predicted HbA 1c , or the residual from the regression line. Aside from the ACCORD trial, the value of HGI has been shown in type 1 diabetes patients in the Diabetes Control and Complications Trial (DCCT) trial, where HGI was a strong predictor of the risk and progression of nephroand retinopathy. 22 The aim of this study is to provide evidence for the clinical relevance of HGI as independent predictor of diabetes-related complications beyond other measures, such as HbA 1c . For this, we conducted a post hoc analysis of the AleCardio trial. 23 We addressed the following questions: is there an association between HGI and diabetes-related complications in terms of (1) primary outcome MACE (composite of cardiovascular mortality, nonfatal myocardial infarction and nonfatal stroke), (2) cardiovascular mortality, (3) total mortality and (4) hypoglycaemia.
Methods

AleCardio trial
The AleCardio trial included 7226 patients, who were or had been hospitalized for an acute coronary syndrome (ACS) and had established or newly diagnosed type 2 diabetes. The trial was designed to compare effects of treatment with either aleglitazar 150 mg or placebo, added to standard of care. The trial was ended prematurely after a median follow-up of two years because of futility for efficacy (no decrease in cardiovascular events) and increased risk of adverse events (heart failure, bone fractures and gastrointestinal haemorrhage) in the aleglitazar group. Detailed descriptions of study protocol and outcomes have been published. 23, 24 Data were obtained from the coordinating centre after approval of the steering committee.
Outcomes
Outcome measures were time to first occurrence of (1) the original primary outcome of AleCardio, being the composite of cardiovascular mortality, nonfatal myocardial infarction and nonfatal stroke (MACE), (2) cardiovascular mortality, (3) total mortality and (4) hypoglycaemia. Cardiovascular death included sudden death, or death due to acute myocardial infarction, heart failure, cerebrovascular events and other presumed cardiovascular deaths (fully documented and not ascribable to a non-cardiovascular cause). Hypoglycaemic episodes were defined as symptoms resolving with food intake, subcutaneous glucagon or intravenous glucose and/or plasma glucose levels <2.8 mmol/l (<50 mg/dl), regardless of the presence of symptoms. 
HGI
Statistical analysis
We compared baseline characteristics between the low, intermediate and high HGI subgroup using analysis of variance or Kruskal-Wallis for continuous variables, depending on the distribution, and Chi-square for categorical variables. We used Cox proportional hazard regression models to analyse the association between baseline HGI and time to event for all outcomes, with adjustment for covariates. All Cox models were stratified by ACS index event (myocardial infarction versus unstable angina) and presence or absence of reperfusion therapy during the index event. First, we ascertained that treatment allocation did not influence the relation between HGI subgroups and outcomes. Therefore, we studied the interaction between treatment and HGI subgroup, by adding the interaction between HGI subgroup and treatment to the model. Without interaction, the effect of HGI on outcomes is considered equal across treatment groups and the association between HGI and outcomes could be assessed irrespective of treatment, for the low, intermediate and high HGI subgroup, as well for HGI as a continuous variable. We included the following covariates in our model: age (<50 years, 50-64 years, 65-74 years, >75 years), sex, race (Asian, African descent, Caucasian, other), body mass index, systolic blood pressure, diastolic blood pressure, haemoglobin, renal function (estimated glomerular filtration rate), low-and high-density lipoprotein cholesterol, triglycerides, duration of type 2 diabetes, use of anti-hyperglycaemic agents (insulin, biguanides, sulphonylureas), history of retinopathy and smoking (past/current, never). Subsequently, in order to assess the predictive value of HGI above HbA 1c we performed an additional adjustment for HbA 1c and analysed the association between HbA 1c (subgroups and continuous) and outcomes. Missing covariate data were replaced with use of multiple imputation (Markov chain Monte Carlo method). Results were considered significantly different at a p-value of <0.05. Statistical analyses were performed using SAS statistical software version 9.2 (SAS Institute, Cary, NC, USA).
Results
There were significant baseline differences between HGI subgroups (Table 1) . Median baseline HbA 1c increased in subsequent HGI subgroups (p < 0.001). Mean baseline FPG was highest in the high HGI subgroup and lowest in the intermediate subgroup (p < 0.001). Male:female ratio was 1:3 for all HGI subgroups. Patients in the high HGI subgroup were significantly younger, had a longer duration of diabetes (7.8 years in the high versus 6.7 years in the intermediate Regardless of HGI, treatment with aleglitazar was associated with a higher risk for hypoglycaemia, but not with a higher risk for MACE and mortality, in accordance with results from the intention-to-treat population of the AleCardio trial (Supplementary  Material Table 1 ). There was no interaction between HGI subgroup and treatment allocation, so we determined hazard ratios for each outcome irrespective of treatment allocation (Table 2) . Hypoglycaemia occurred less often in the low HGI subgroup as compared with the intermediate subgroup (11% versus 14%, unadjusted hazard ratio 0.77; 95% confidence interval (CI) 0.65-0.91, p ¼ 0.002) and high subgroup (11% versus 17%, unadjusted hazard ratio 0.62; 95% CI 0.52-0.73, p < 0.001). However, these differences between HGI subgroups disappeared after adjustment for covariates, in particular for duration of diabetes, insulin and sulphonylurea use. In the multivariate model, cardiovascular mortality occurred less often in the low HGI subgroup as compared with the high HGI subgroup (2.5% versus 3.3%, hazard ratio 0.64; 95% CI 0.44-0.93, p ¼ 0.020). The same was seen for total mortality (3.6% versus 4.4%, hazard ratio 0.69; 95% CI 0.50-0.95, p ¼ 0.025). The two covariates specifically influencing this association were age and glomerular filtration rate. Using continuous HGI as predictor, every percentage increase in HGI was associated with a 16% increased risk for both cardiovascular and total mortality (adjusted hazard ratio 1.16; 95% CI 1.06-1.27, p ¼ 0.001 and hazard ratio 1.16; 95% CI 1.04-1.28, p ¼ 0.005, respectively) ( Table 3 ). There was no association between continuous HGI and MACE (adjusted hazard ratio 1.06; 95% CI 1.00-1.12, p ¼ 0.063) and hypoglycaemia (adjusted hazard ratio 1.03; 95% CI 0.98-1.08, p ¼ 0.248).
To assess whether HGI would be a better predictor of cardiovascular and total mortality than HbA 1c , we first analysed the same model with additional adjustment for HbA 1c . This resulted in the disappearance of the effect of HGI on mortality (HbA 1c adjusted hazard ratio 0.93; 95% CI 0.60-1.45, p ¼ 0.747 for total mortality and hazard ratio 0.92; 95% CI 0. 
Discussion
Our study showed that high HGI patients were at greater risk for both cardiovascular and total mortality as compared with their low HGI counterparts. This association was only seen after adjustment for the effects of the younger age and higher glomerular filtration rate in the high HGI subgroup, both likely protective confounders in terms of mortality. Theoretically, the higher cardiovascular mortality rates in the high HGI patients might be due to enhanced glycation of other proteins, promoting earlier atherogenesis. The HGI can also be a marker of some other, as yet unknown, mechanism, but a solid pathophysiological explanation is lacking. When assessing HGI as continuous variable, every percentage increase in HGI was associated with a 16% increase in the risk for both cardiovascular and total mortality. However, there seems little or no added value for HGI in addition to HbA 1c when predicting outcomes, which is a strong predictor for diabetes complications itself and statistically strongly related to HGI (since HGI is HbA 1c corrected for FPG). This was supported by the fact that the predictive value of HGI disappeared after correction for the effects of HbA 1c , and HbA 1c as predictor, both categorized and continuous, gave more or less equal hazard ratios for cardiovascular and total mortality.
The association between HGI and adverse outcomes in previous studies might be explained by the possibility of therapy-induced hypoglycaemia, since patients in the high HGI subgroup need and likely get more intensive treatment to lower their HbA 1c than is necessary to control their blood glucose. This was supported by the fact that in the ACCORD trial, the risk for severe hypoglycaemia was paradoxically associated with higher HbA 1c values (i.e. mostly high HGI patients). 17 In our study, hypoglycaemia also occurred more frequently in high HGI patients as compared with low and intermediate HGI patients. However, high HGI patients had an on average longer duration of diabetes and used more insulin and sulphonylurea, and the effect of HGI on hypoglycaemia disappeared after adjustment for these plausible confounders.
The present findings need careful interpretation with respect to the results from Hempe et al. in the ACCORD trial. ACCORD's primary aim was to investigate the effect of intensive glucose lowering treatment on outcomes, whereas AleCardio was not only aiming to achieve glucose lowering with aleglitazar, but also to take possible advantage of non-glucose mediated effects of this peroxisome proliferator-activated receptor alpha/gamma agonist. After one year of treatment with aleglitazar, HbA 1c levels were on average lowered by 0.9%, in contrast to a rapid 1.7% lowering in the intensive treatment arm of the ACCORD trial. Also, AleCardio patients had shorter follow-up (median of two years to a median of 3.5 years in the ACCORD). Moreover, the AleCardio trial included type 2 diabetes patients who all experienced an ACS. This in contrast to the ACCORD trial, where only 35% had a previous cardiovascular event. This difference in a priori risk was reflected in the higher follow-up event rates in AleCardio patients for both the primary outcome MACE (9.5-10.0% in AleCardio versus 6.9-7.2% in ACCORD, depending on treatment allocation) and for cardiovascular death (2.7-3.1% in AleCardio versus 1.8-2.6% in ACCORD).
In our study population we found a wide variance in HbA 1c at a certain plasma glucose level. This supports previous observations on the substantial amount of the variation in the propensity for glycation between individuals that cannot be explained by (fasting) plasma glucose levels, in patients with and without diabetes (both types 1 and 2). [25] [26] [27] [28] [29] [30] When translating this variance in the HGI, the high HGI subgroup has on average a 1.58% higher observed HbA 1c than predicted. Besides having higher HbA 1c values, patients in the high HGI group are younger, have a longer duration of diabetes and more frequently use insulin than their low and intermediate HGI counterparts. These findings are in accordance with those found in the high HGI patients in ACCORD and other studies. 21, 22 We found a higher prevalence of retinopathy at baseline in the high HGI group, also in accordance with findings from the DCCT. The high HGI group consisted of more non-Caucasians, which is in agreement with the ACCORD findings, but also with numerous epidemiological studies showing higher HbA 1c levels in Hispanic, Asian and African descents compared with Caucasians. [31] [32] [33] [34] [35] [36] [37] [38] [39] High HGI patients showed a significantly greater decline in HGI during follow-up, when compared with low and intermediate HGI patients, not ascribable to treatment allocation. This suggests regression towards the mean, although mean HGI at the end follow-up remained highest in high HGI patients. The considerable change in HGI that we observed is in contrast with previous reports, where HGI was more consistent over a period of several weeks up to six years, in children and adolescents with type 1 diabetes and people without diabetes. 40, 41 To determine HGI we used time-matched FPG, so we could not correct for the influence of daytime To assess a more reliable estimate of the mean glucose, diurnal (continuous) glucose profiles are to be preferred over FPG alone. However, ACCORD also used FPG only and FPG correlates highly with mean or continuous measurements. Furthermore, it is important to once more point out that the HGI is not a direct measurement of a known physiological reaction, but only a mathematical reflection of the biological diversity in propensity for glycation. Although numerous explanations for the interindividual variation in glycation have been proposed, a convincing physiological mechanism has not yet emerged.
In conclusion, our findings in a well-defined cohort of 6458 type 2 diabetes patients diagnosed with an ACS show that HGI predicts cardiovascular and total mortality, both in continuous and categorized models. The risk associated with HGI was, however, not seen over and above HbA 1c , which is a strong predictor of these complications by itself and does not require a population based regression calculation as does HGI. From our perspective, HGI is no better than HbA 1c as predictor of risk for complications.
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